Screener
Bristol-Myers Squibb BMY Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Bristol-Myers Squibb in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Bristol-Myers Squibb’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 11:10 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000014272-26-000020
FAQ
- What is Bristol-Myers Squibb's accounts payable?
- Bristol-Myers Squibb (BMY) reported accounts payable of $4.16B in Q2 2026.
- How has Bristol-Myers Squibb's accounts payable changed year-over-year?
- Bristol-Myers Squibb's accounts payable decreased by 23.4% year-over-year, from $5.43B to $4.16B.
- What is the long-term trend for Bristol-Myers Squibb's accounts payable?
- Over 5 years (2020 to 2025), Bristol-Myers Squibb's accounts payable has grown at a 5.7% compound annual growth rate (CAGR), from $2.71B to $3.58B.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Bristol-Myers Squibb's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude